CDTX
Price
$21.54
Change
-$0.84 (-3.75%)
Updated
Feb 21 closing price
Capitalization
235.76M
NBY
Price
$0.63
Change
-$0.01 (-1.56%)
Updated
Feb 21 closing price
Capitalization
3.08M
Ad is loading...

CDTX vs NBY

Header iconCDTX vs NBY Comparison
Open Charts CDTX vs NBYBanner chart's image
Cidara Therapeutics
Price$21.54
Change-$0.84 (-3.75%)
Volume$51.84K
Capitalization235.76M
NovaBay Pharmaceuticals
Price$0.63
Change-$0.01 (-1.56%)
Volume$82.16K
Capitalization3.08M
CDTX vs NBY Comparison Chart
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. NBY commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Hold and NBY is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (CDTX: $24.00 vs. NBY: $0.67)
Brand notoriety: CDTX and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 80% vs. NBY: 7%
Market capitalization -- CDTX: $235.76M vs. NBY: $3.08M
CDTX [@Biotechnology] is valued at $235.76M. NBY’s [@Biotechnology] market capitalization is $3.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileNBY’s FA Score has 0 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • NBY’s FA Score: 0 green, 5 red.
According to our system of comparison, CDTX is a better buy in the long-term than NBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 4 TA indicator(s) are bullish while NBY’s TA Score has 4 bullish TA indicator(s).

  • CDTX’s TA Score: 4 bullish, 6 bearish.
  • NBY’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NBY is a better buy in the short-term than CDTX.

Price Growth

CDTX (@Biotechnology) experienced а +9.14% price change this week, while NBY (@Biotechnology) price change was +3.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

CDTX is expected to report earnings on Aug 13, 2024.

NBY is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($236M) has a higher market cap than NBY($3.08M). NBY YTD gains are higher at: 11.681 vs. CDTX (-10.714). NBY has higher annual earnings (EBITDA): -6.52M vs. CDTX (-127.83M). CDTX has more cash in the bank: 127M vs. NBY (776K). NBY has less debt than CDTX: NBY (1.26M) vs CDTX (3.94M). CDTX has higher revenues than NBY: CDTX (44.7M) vs NBY (13.8M).
CDTXNBYCDTX / NBY
Capitalization236M3.08M7,667%
EBITDA-127.83M-6.52M1,960%
Gain YTD-10.71411.681-92%
P/E RatioN/AN/A-
Revenue44.7M13.8M324%
Total Cash127M776K16,366%
Total Debt3.94M1.26M312%
FUNDAMENTALS RATINGS
CDTX vs NBY: Fundamental Ratings
CDTX
NBY
OUTLOOK RATING
1..100
277
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3663
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDTX's Valuation (35) in the Biotechnology industry is in the same range as NBY (41). This means that CDTX’s stock grew similarly to NBY’s over the last 12 months.

CDTX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NBY (100). This means that CDTX’s stock grew similarly to NBY’s over the last 12 months.

CDTX's SMR Rating (99) in the Biotechnology industry is in the same range as NBY (100). This means that CDTX’s stock grew similarly to NBY’s over the last 12 months.

CDTX's Price Growth Rating (36) in the Biotechnology industry is in the same range as NBY (63). This means that CDTX’s stock grew similarly to NBY’s over the last 12 months.

CDTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NBY (100). This means that CDTX’s stock grew similarly to NBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXNBY
RSI
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
84%
Bullish Trend 6 days ago
82%
Momentum
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
76%
MACD
ODDS (%)
Bullish Trend 6 days ago
87%
Bearish Trend 6 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
82%
Bearish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
82%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
87%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 28 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 6 days ago
89%
Aroon
ODDS (%)
Bearish Trend 6 days ago
81%
Bullish Trend 6 days ago
90%
View a ticker or compare two or three
Ad is loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with WINT. These tickers have moved in lockstep 94% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then WINT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
+0.25%
WINT - CDTX
94%
Closely correlated
-20.01%
NBY - CDTX
93%
Closely correlated
+1.54%
NCNA - CDTX
93%
Closely correlated
+3.29%
SNPX - CDTX
93%
Closely correlated
-6.31%
BPTSY - CDTX
92%
Closely correlated
N/A
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+1.54%
CDTX - NBY
93%
Closely correlated
+0.25%
NCNA - NBY
93%
Closely correlated
+3.29%
WINT - NBY
92%
Closely correlated
-20.01%
SNPX - NBY
91%
Closely correlated
-6.31%
RNAC - NBY
91%
Closely correlated
-0.76%
More